Skip to main content
EVAX
NASDAQ Life Sciences

Shareholders Approve Highly Dilutive Convertible Note & Warrant Authorizations

Analysis by Wiseek.aiReviewed by Editorial Team
Sentiment info
Negative
Importance info
9
Price
$4.5
Mkt Cap
$37.531M
52W Low
$1.25
52W High
$12.15
Market data snapshot near publication time

summarizeSummary

Evaxion A/S shareholders approved new authorizations for convertible loan notes and an increase in warrant authorizations, representing a significant potential for future share dilution.


check_boxKey Events

  • Authorization for Convertible Loan Notes

    Shareholders authorized the board to obtain loans against convertible loan notes for up to DKK 73,500,000 nominal value. If fully converted, this could result in the issuance of 294,000,000 new shares, representing a potential dilution of approximately 70.50% of the current outstanding shares. The conversion price will be determined at market price (within +/-10% of the listed price).

  • Increased Warrant Authorization

    The existing authorization to issue warrants to employees and management was increased from DKK 6,857,257 to DKK 11,900,000 nominal value. This new authorization allows for the potential issuance of up to 47,600,000 shares, which would result in a potential dilution of approximately 11.41% of the current outstanding shares. The exercise price for these warrants will be at market price.

  • New Board Member Elected

    Jens Bitsch-Nørhave was elected as a new member of the board of directors.


auto_awesomeAnalysis

Evaxion A/S shareholders approved significant increases in the company's ability to issue new shares through convertible loan notes and warrants. The authorization for convertible loan notes could lead to a potential dilution of approximately 70.50% of current outstanding shares, while the increased warrant authorization could result in an additional 11.41% dilution. These authorizations provide the company with mechanisms for future capital raises and employee incentives but signal a substantial potential for dilution for existing shareholders. The approval of a new board member is a routine governance update.

At the time of this filing, EVAX was trading at $4.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.5M. The 52-week trading range was $1.25 to $12.15. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed EVAX - Latest Insights

EVAX
Apr 27, 2026, 8:10 AM EDT
Filing Type: 6-K
Importance Score:
7
EVAX
Apr 22, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
9
EVAX
Apr 17, 2026, 3:30 PM EDT
Filing Type: 6-K
Importance Score:
8
EVAX
Apr 17, 2026, 3:20 PM EDT
Filing Type: 6-K
Importance Score:
7
EVAX
Apr 17, 2026, 3:00 PM EDT
Source: GlobeNewswire
Importance Score:
7
EVAX
Apr 07, 2026, 8:05 AM EDT
Filing Type: 6-K
Importance Score:
7
EVAX
Mar 30, 2026, 8:05 AM EDT
Filing Type: 6-K
Importance Score:
8
EVAX
Mar 19, 2026, 9:00 AM EDT
Filing Type: 6-K
Importance Score:
9
EVAX
Mar 17, 2026, 4:40 PM EDT
Filing Type: 6-K
Importance Score:
7
EVAX
Mar 05, 2026, 9:28 AM EST
Source: GlobeNewswire
Importance Score:
9